Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 16/20 | 0.45 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.39 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807146 | 0.92 | KCNH2 (0.41) | ITGAVITGB3ITGB6KCNH2ITGB5 | |
| SCHEMBL12807006 | 0.81 | ITGAV (0.58) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL21766819 | 0.80 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL1814245 | 0.77 | KCNH2 (0.38) | ITGAVITGB3ITGB6KCNH2ITGB5 | |
| SCHEMBL1827947 | 0.77 | ITGAV (0.54) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL13833866 | 0.76 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL30336058 | 0.76 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL12807123 | 0.75 | KCNH2 (0.41) | ITGAVITGB3ITGB6KCNH2ITGB5 | |
| SCHEMBL12807162 | 0.74 | KCNH2 (0.40) | ITGAVITGB3ITGB6KCNH2 | |
| SCHEMBL21780649 | 0.72 | ITGAV (0.60) | ITGAVITGB3ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| EP-2493888-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011059839-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ITGAV 4645/4885ITGB3 4292/4885ITGB6 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.